OR WAIT null SECS
© 2025 MJH Life Sciences™ , Pharmaceutical Technology - Pharma News and Development Insights. All rights reserved.
Most of the company’s new additions, if not already online, will be scheduled for commissioning, validation, or qualification before the fourth quarter of 2025.
The global contract packaging organization Tjoapack is announcing an expansion of its contract packaging and cold chain storage services in both the United States and The Netherlands (1). The company intends to scale its logistics infrastructure to meet rising demand it has seen for injectables and biologics, as well as bolster its supply chain resilience and deliver faster turnaround times and greater flexibility for clients.
In a press release on June 5, 2025, Tjoapack detailed the changes planned for the facilities in Clinton, Tenn., in the US, and at Etten-Leur in The Netherlands.
At the Clinton site, Tjoapack is completing installation of two advanced packaging lines that will support high-throughput, sterile packaging operations (1). A line expected to be completed in the second quarter of 2025 is high-speed and fully automated for vial packaging, with an annual processing capability of 20 million vials—including integrated labeling, cartooning, and serialization. In the third quarter, a semi-automated auto-injector line that offers end-to-end traceability and labeling will be scheduled for qualification. Cold storage capacity at this site has been expanded and validated, providing a total of 160 good manufacturing practice-compliant pallet spaces in controlled 2–8°C conditions.
The Etten-Leur facility has also seen its cold chain capacity increase, bringing on 84 additional pallet spaces to push its total to 120, under the same temperature guidelines. This site, according to Tjoapack, additionally has completed its first commercial project for prefilled syringe (PFS) packaging (1). The fully automated PFS line offers syringe assembly with or without safety devices, automated plunger rod insertion, and insertion of ancillary components like needles, among other features.
“These upgrades directly address the accelerating needs of our clients in the biologics and sterile injectable space,” said Dexter Tjoa, CEO of Tjoapack, in the press release (1). “We are committed to building scalable, compliant infrastructure that ensures the efficient delivery of vital therapies without compromising on flexibility or quality. By strengthening its injectable packaging and cold chain capabilities, Tjoapack is supporting a wider range of primary container formats, including vials, ampoules, syringes, and auto-injectors, while scaling capacity to better serve both new and existing clients across North America and Europe.”
In the January/February 2025 edition of Pharmaceutical Technology®, Joe Compton, senior director of Business Development and Alliance Management for Tjoapack US, said packaging trends in 2025 would be driven in part by the rise of biologics self-administration.
“The development of PFS and auto-injectors has simplified the injection process, making it easier for patients to self-administer biologics at home,” Compton said (2). “Auto-injectors are designed for intuitive use, often requiring a single step to deliver the medication. This eliminates the complexity of traditional injections, which involve multiple steps like preparing the syringe, measuring the dose, and administering the injections. Auto-injectors feature ergonomic designs and clear instructions, making them easy to handle and operate, even for patients with limited dexterity or those unfamiliar with injections.”
At the Drug, Chemical & Associated Technologies Association (DCAT) Week in March 2025, Peter Belden, president of Tjoapack US, spoke to Pharmaceutical Technology® Group about recent innovations in biopharmaceutical manufacturing, and Tjoapack’s strategy in responding to those trends.
“We've been investing heavily in expanding our cold chain capabilities, in expanding our capability and capacity to package unique configuration for injectable products, whether that is a product that comes to us in a syringe format, a vial format, or an auto injector format,” Belden said (3). “[We have] the ability to either automate or semi-automate, label, and then finish [to] pack those products while maintaining tight control of time [and] temperature to allow for packaging, and then getting those materials and finished goods back into cold storage.”
The full interview with Belden can be seen at this link.
1. Tjoapack. Tjoapack Continues to Expand Its Global Infrastructure with Strategic Investments in Injectable Packaging and Cold Chain Capabilities. Press Release. June 5, 2025.
2. Compton, J. Meeting Secondary Packaging Challenges of Innovative Delivery Systems for Biologics. Pharmaceutical Technology 2025, 49 (1).
3. Haigney, S. DCAT Week 2025: Packaging Innovations. PharmTech.com, March 17, 2025.
